Avecho Biotechnology Limited
Avecho Biotechnology Limited (AVEFF) Revenue
Annual & quarterly revenue history · segment & region breakdown
AVEFF · revenue · updated Jun 9, 2026
Core revenue metrics
Trailing 12 monthsAvecho Biotechnology Limited trailing twelve-month (TTM) revenue is $0.00B, a decrease of 4.38% year-over-year from $0.00B in FY2025.
Revenue trend
2025 – 2006 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.00B | -$0.00B | -4.38% |
| 2024-12-31 | $0.00B | +$0.00B | +173.25% |
| 2023-12-31 | $0.00B | -$0.00B | -60.73% |
| 2022-12-31 | $0.00B | +$0.00B | +51.97% |
| 2021-12-31 | $0.00B | +$0.00B | +106.33% |
| 2020-12-31 | $0.00B | -$0.00B | -90.92% |
| 2019-12-31 | $0.00B | +$0.00B | +238.50% |
| 2018-12-31 | $0.00B | +$0.00B | +8.87% |
| 2017-12-31 | $0.00B | -$0.00B | -27.58% |
| 2016-12-31 | $0.00B | -$0.00B | -27.49% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Avecho Biotechnology Limited receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Avecho Biotechnology Limited reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in AUD.
Data sourced from Avecho Biotechnology Limited's 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
AVEFF revenue · 4 questionsAVEFF's trailing twelve-month (TTM) revenue is $0.00B. That is a decrease of 4.38% year-over-year from $0.00B in FY2025.
▸ Source: FMP · Avecho Biotechnology Limited SEC filings · GAAP · Avecho Biotechnology Limited SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026